395 related articles for article (PubMed ID: 25286976)
21. The Future of Precision Medicine in Oncology.
Millner LM; Strotman LN
Clin Lab Med; 2016 Sep; 36(3):557-73. PubMed ID: 27514468
[TBL] [Abstract][Full Text] [Related]
22. Clinical trials in the era of personalized oncology.
Maitland ML; Schilsky RL
CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
[TBL] [Abstract][Full Text] [Related]
23. Small molecules, big impact: 20 years of targeted therapy in oncology.
Bedard PL; Hyman DM; Davids MS; Siu LL
Lancet; 2020 Mar; 395(10229):1078-1088. PubMed ID: 32222192
[TBL] [Abstract][Full Text] [Related]
24. Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
Christenson ES; Jaffee E; Azad NS
Lancet Oncol; 2020 Mar; 21(3):e135-e145. PubMed ID: 32135117
[TBL] [Abstract][Full Text] [Related]
25. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).
Golan T; Milella M; Ackerstein A; Berger R
J Exp Clin Cancer Res; 2017 Dec; 36(1):192. PubMed ID: 29282151
[TBL] [Abstract][Full Text] [Related]
26. Precision Medicine in Pediatric Oncology.
Vo KT; Parsons DW; Seibel NL
Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
[TBL] [Abstract][Full Text] [Related]
27. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
28. Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch JW; Metzeler KH; Jung A; Riedmann K; Jost PJ; Weichert W; Kirchner T; Heinemann V; Westphalen CB
Eur J Cancer; 2017 Sep; 82():72-79. PubMed ID: 28648701
[TBL] [Abstract][Full Text] [Related]
29. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
[No Abstract] [Full Text] [Related]
30. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
31. Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancers.
Fontanella C; Aprile G; Scartozzi M; Lederer B; Cascinu S; von Minckwitz G
Future Oncol; 2014 Oct; 10(12):1901-6. PubMed ID: 25386808
[TBL] [Abstract][Full Text] [Related]
32. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
33. Successes and limitations of targeted cancer therapy in melanoma.
Romano E; Michielin O
Prog Tumor Res; 2014; 41():78-88. PubMed ID: 24727988
[TBL] [Abstract][Full Text] [Related]
34. Cancer genomics and clinical practice: how can we close the gap more quickly?
Konecny GE
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):1-3. PubMed ID: 27941363
[No Abstract] [Full Text] [Related]
35. [Drug research in oncology; advances in the genome era].
Bins S; Schellens JH; Voest EE; Sleijfer S
Ned Tijdschr Geneeskd; 2014; 158():A6801. PubMed ID: 24618235
[TBL] [Abstract][Full Text] [Related]
36. Molecular Tumor Boards: Realizing Precision Oncology Therapy.
Patel M; Kato SM; Kurzrock R
Clin Pharmacol Ther; 2018 Feb; 103(2):206-209. PubMed ID: 29134641
[TBL] [Abstract][Full Text] [Related]
37. 2010 translational bioinformatics year in review.
Altman RB; Miller KS
J Am Med Inform Assoc; 2011; 18(4):358-66. PubMed ID: 21672905
[TBL] [Abstract][Full Text] [Related]
38. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
39. Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives.
Metzger-Filho O; Moulin C; Awada A
Curr Clin Pharmacol; 2010 Aug; 5(3):166-77. PubMed ID: 20406173
[TBL] [Abstract][Full Text] [Related]
40. Personalised cancer medicine.
Jackson SE; Chester JD
Int J Cancer; 2015 Jul; 137(2):262-6. PubMed ID: 24789362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
